On March 31, 2014, after 39 years of service, I retired from Juntendo University. To mark the advent of my retirement, I was asked to submit a summary of my career activity to the Juntendo Medical Journal of the retirement speech that I had given at the Juntendo Medical Society meeting, which has a history exceeding 175 years.
Part one of my career summary will focus on the 9-year period after my becoming a resident in 1974 and the completion of the residency program. Specifically, I will focus on the studies that I conducted during those years, which included experiments on immune abnormalities associated with severe burn injuries. A clinical study on direct surgical intervention (Sugiura Method) for esophageal varices was also conducted. These nine years extend from 1976 At that time, the most commonly used treatment strategy for severe burn injuries (usually burns covering more than 30% of the total body surface) was to wait for one week after the injury to allow stabilization of the patientʼs general condition, to then achieve complete burn eschar removal, and finally perform skin grafting to cover the wound surfaces with clean skin as expeditiously as possible. However, even after successful skin grafting, many of these patients died of severe infections (particularly sepsis). These infectious complications tended to occur approximately one month after the skin grafting procedure. Thus, there was an ongoing debate as to the most appropriate measures to be taken against these infections.
At that time, immune deficiency was being considered as a major factor contributing to the high incidence of severe infections in patients with severe burn injuries.
Given this background, I began a serious investigation of immune competence in patients with severe burn injuries, focusing on both the humoral and the cellular aspects of the immune system.
First, immunity in clinical cases (with burns covering more than 30% of the total body surface area) was assessed. My findings revealed that some of the severe cases had a low white blood cell count. Most notably, outcomes worsened as lymphocyte counts decreased. Parameters of cellular immunity were also measured, and the results confirmed decreased numbers of T cells.
Based on these findings, I hypothesized that the main cause of decreased immunity in patients with severe burn injuries was decreased T-cell-medi-ated immunity. The next step in this research was an endeavor to demonstrate my hypothesis by conducting experiments.
First, to assess cellular immunity in C3He mice (hereinafter referred to as"mice" ), lymphocytes were isolated from their blood. Methods of measuring T cells and B cells were then established.
Under general anesthesia, third-degree burns were created on 10%, 30%, 50%, and 80% of the body surface areas of mice. Their mortality rates were then determined. All of the mice with over 50% burns died immediately after the injury, while the mortality rate in those with 30% burns was 50%. Therefore, the decision was made that mice with burns covering 30% of the body surface area would be used for all subsequent experiments.
Comparisons between the mice with severe burn injuries and their healthy counterparts showed an obvious decrease in T cell numbers in those with severe burn injuries.
In the next experiment, infection was induced in mice with severe burn injuries.
After applying pseudomonas aeruginosa (Y1 strain of pseudomonas aeruginosa provided by the Department of Bacteriology [headed by Professor Yokota]) to the wound surfaces, T cells and B cells in these mice were measured over time. This experiment yielded the following findings:
1)The survival rate was clearly lower in the mice with than in those without pseudomonas aeruginosa exposure. 2)Microscopic tests on ascitic fluid collected from the abdominal cavities of the mice with pseudomonas aeruginosa revealed proliferation of this organism. Low lymphocyte counts and decreased numbers of T cells were simultaneously documented, revealing decreased cellular immunity (Figure-1) . 3)A subgroup of mice underwent inoculation with gamma globulin + TOB prior to sustaining severe burns and experimental application of pseudomonas aeruginosa. The mortality rate was lower in the mice receiving than in those not given this inoculation. 4)Some of the mice were inoculated with OK-432, which is known to be a cellular immunopotentiator, but this intervention yielded no discernible effects. Based on these findings, I completed my Thereafter, surgical treatment of esophageal varices (esophageal transection by the Sugiura method) became the main specialty of the department.
Later, as the head of the Second Department of Gastroenterological and General Surgery, Professor Sugiura broke new ground in the field of hepato-biliaryi-pancreatic disease; he devoted himself especially to promoting surgical treatment of esophageal varices and established the Sugiura Method, which is a transthoracic or transabdominal esophageal transection procedure for esophageal varices. I examined the liver functions of patients who had undergone esophageal transection in detail, and thereby demonstrated that the Sugiura Method did not affect hepatic functions. This research was also published, as follows. Please refer to these publications for details: Professor Sugiura successfully performed over 850 esophageal transections during his long and productive career. Unfortunately, on July 28, 1988, he suffered cardiopulmonary arrest while undergoing left hepatic lobectomy for carcinoma in the left hepatic lobe, and despite an attempt at emergency coronary-artery bypass surgery in the operating room, Professor Sugiura passed away at the age of only 63.
Part 2
At the same time that provision of medical care services began at Juntendo University Urayasu Hospital in April 1984, I transferred to the Urayasu Hospital with Professor Yagi and became a lecturer of the Second Department of Surgery (under the auspices of Juntendo University Urayasu Hospital). Working with Professor Yagi, the following academic milestones were achieved:
June 1987: Hosted the 23rd Japan Association for In 2004, I was awarded a professorship at the Department of Emergency Medical Care at Juntendo University Urayasu Hospital and was assigned the task of launching the department. Thanks in large part to invaluable assistance from other faculty members, the department was approved by Chiba Prefecture as the second tertiary emergency and critical care center in the South Tokatsu Medical Care Zone.
In 2006, the Ministry of Health, Labour and Welfare established the System of Designated Regional Cancer Care Hospitals. This was prompted by concern over the increased number of patients dying of cancer. In October 2007, Juntendo University Urayasu Hospital was selected by Chiba Prefecture as a designated regional cancer care hospital to assume the central role in the South Tokatsu Medical Care Zone. I was assigned to launch the Cancer Center, serving as its director, and in October of the same year, became a professor of the Department of Malignant Oncology (at Urayasu). As the director of the Cancer Center, I initiated a policy aimed at providing medical services centered on cancer chemotherapy in May 2008 and after serving for five years, stepped down from this post on March 31, 2013.
I will now briefly elaborate on the Cancer Center at Juntendo University Urayasu Hospital.
It has been slightly more than five years since the Cancer Center was first opened on May 15, 2008, as a result of the selection of Juntendo University Urayasu Hospital as a designated regional cancer care hospital.
As of November 2013, the center has 264 doctors. Of these, 194 are qualified specialists. Among them, there are 17 tentative instructors in clinical oncology, 5 general clinical oncologists, and 2 cancer drug therapy specialists certified by the Japanese Society of Medical Oncology. The center covers every stage of cancer treatment from the initial diagnosis to the administration of a wide range of therapies, through end-of-life care. Many cancer patients are elderly and thus prone to the development of complications. However, the center is well equipped to provide treatment for such patients within the facility.
The Cancer Center has seven subcommittees, which are the Chemotherapy Steering Committee, Drug Regimen Review Committee, Palliative Care Unit Steering Committee, Cancer Treatment Collaboration Unit/Counseling and Support Staff Conference, Cancer Registration Unit Steering Subcommittee, Cancer Board Steering Committee, and Critical Path Steering Subcommittee. The center operates organically to provide appropriate support for patients and plans to further incorporate beneficial functions for cancer patients to fulfill its role as a leading cancer care provider.
Cancer care requires a multidisciplinary treatment approach consisting of surgery, chemotherapy, and radiation therapy. Among these three mainstays of managing patients with malignant diseases, the Cancer Center specializes in chemotherapy. In fact, the number of patients undergoing chemotherapy at the center increased from approximately 200 a year in 2008 to more than 500 a month in 2014. With the ongoing advancements in chemotherapy, the number of drug regimens has also risen to approximately 300. Further progress in this field is anticipated.
Another major pillar of the Cancer Centerʼ s comprehensive treatment strategy is palliative care. In addition to the regular palliative care workshop for medical professionals (mostly doctors) that has been held since 2009, the Advanced Program of the palliative care workshop was initiated in 2012. In 2013, the palliative care workshop for nurses was also held for the first time.
Counseling and support care constitute another extremely important role that a designated regional cancer care hospital must fulfill. Today, the annual number of telephone consultations far exceeds 1,000 and the annual number of face-to-face consultations is over 3,300, totaling 4,500 consultations a year.
An original project of the Cancer Center, known as"Patient Salon: Aobeka" , is held four times a year, involving about five persons each time. It has been held 16 times, to date.
In recent years, there has been marked forward movement in efforts to protect cancer patients in their daily lives. To achieve this aim, the center has been collaborating with a non-profit organization, designated"Living with Cancer" , and has thereby become the first organization in Chiba Prefecture to host monthly consultations provided by labor and social security attorneys and financial planners. These efforts have been met with a highly favorable response.
Education and training also constitute vital projects for designated regional hospitals. The Cancer Center has been holding lectures and training seminars for medical professionals within and outside of the hospital system as many as five times a year. Furthermore, with the implementation of oral care practice, postoperative outcomes have improved and chemotherapy can now be performed more safely. Oral care is a very important aspect of cancer treatment, and the center has actively been collaborating with the Urayasu Dental Association to achieve this aim.
Finally, sufficient nutrient intake is an extremely important facet of comprehensively managing cancer patients. The Cancer Center has also worked cooperatively with a non-profit organization, the"Medical Welfare Network Chiba" , for the promotion of optimal food products for patient care.
On March 31, 2014, I retired from Juntendo University after 39 years of service. It has been my honor and privilege to serve Juntendo University Hospital and its patients.
